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The incidence of multidrug-resistant (MDR)
Salmonella Typhimurium infections in humans, and in par-
ticular MDR definitive phage type 104 (DT104), has
increased substantially in many countries in the last 2
decades, often associated with increased illness. To exam-
ine the magnitude of this problem, a survey was conducted
among countries with available antimicrobial resistance or
phage typing surveillance data. A total of 29, primarily
industrialized, countries participated in the survey, which
covered the years 1992–2001. Overall, the incidence of
MDR S. Typhimurium and DT104 increased continuously
during this period, although the problem affected primarily
Europe and North America. The increase appeared to have
peaked in the United Kingdom but not in other countries.
Also, the incidence of quinolone-resistant S. Typhimurium
was increasing. This survey implies that MDR S.
Typhimurium constitutes an increasing public health prob-
lem in large parts of the world and emphasizes the impor-
tance of surveillance and control programs.
I
nfections with nontyphoidal Salmonella have increased
during the last 3–4 decades, and although a decrease has
been reported over the last decade, Salmonella infections
continue to be a major public health concern in many
countries (1–3). These salmonellae are zoonotic, and the
infections are generally foodborne. Although a large num-
ber of Salmonella serotypes exist, the overall increase in
the number of infections is of relatively few emerging
serotypes and phage types. Over periods of several years,
certain Salmonella types have risen and (sometimes) fall-
en within large geographic regions. These meta-outbreaks
are facilitated through the acquisition, by specific types, of
new traits that make them well adapted to spread, as well
as through changes to human society, seen, for instance,
with modern intensified farming and food production
methods and global trade with live breeder animals (2,4,5).
Two prominent examples are the international spread of
S. Enteritidis infections through hens eggs (2,6) and the
emergence over the last 2 decades of multidrug-resistant
(MDR)  Salmonella Typhimurium definitive phage type
104 (DT104).
Nontyphoidal Salmonella causes mild to severe, includ-
ing life-threatening, infections. One study estimated that
600 deaths occur per year in the United States alone due to
infections with nontyphoidal Salmonella serotypes (7). A
recent study in Denmark showed that infection with non-
typhoidal  Salmonella was associated with a 2.5-fold
increased risk for death within 1 year of infection com-
pared with a matched sample from the general Danish pop-
ulation (8). Salmonellae resistant to antimicrobial drugs
appear to pose a particular health risk. Thus, several
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resistant to >1 antimicrobial drugs is associated with
increased risk for hospitalization, invasive illness, and
death (9–15).
In general, antimicrobial drug resistance occurs fre-
quently in zoonotic salmonellae and is largely promoted by
using antimicrobial drugs in food animals (4,16–18). S.
Typhimurium DT104 is commonly resistant to 5 drugs:
ampicillin, chloramphenicol, streptomycin, sulfonamides,
and tetracycline (R-type ACSSuT). S. Typhimurium
DT104 was first isolated in the early 1980s in the United
Kingdom and later became endemic in bovine animals,
from where it spread to the whole food animal production
in that country (5,18). Throughout the 1990s, it spread to
other parts of the world, and it is now a common
Salmonella type in many countries, including the United
States, the United Kingdom, Germany, and France
(2,19–22). DT104 is common in a broad range of food ani-
mals, such as poultry, pigs, and sheep (23). This phage
type has become a matter of concern because of its rapid
international dissemination in the 1990s and its ability to
readily acquire additional resistance traits to other, clini-
cally important antimicrobial drug classes, such as
quinolones, trimethoprim, and cephalosporins. 
A global survey of salmonellosis and Salmonella
serotyping was published in 2002 (24). However, relative-
ly little information has been compiled on the global
spread of DT104 and MDR S. Typhimurium (23).
Therefore, we have conducted a survey to describe the
pandemic of DT104 and MDR S. Typhimurium.
Methods
Participating Countries 
The survey addressed information on antimicrobial
drug resistance testing, phage typing, or both. Since most
countries do not routinely apply these typing methods, the
questionnaire was not simply sent to all World Health
Organization (WHO) member states. Instead, an invitation
to participate in the survey was distributed through the
WHO Global Salm-Surv (GSS) network (25) and directly
to all Enter-Net (26) network countries, plus a group of
large countries known or assumed to have resistance test-
ing or phage typing as an integrated part of their national
Salmonella surveillance system.
A total of 52 questionnaires were sent out in June and
July 2002. Of these, 44 were sent directly to countries
known or assumed to have resistance testing or phage typ-
ing, and 8 were sent out to member states responding to the
GSS invitation. Of the 52 questionnaires, 32 were sent to
countries in the European region, 6 to the American
Region, 7 to the Asian Region, 5 to the African Region,
and 2 to the Oceania Region. Country names and names of
geographic regions and subregions are used as described in
the United Nations classification system (27).
The Questionnaire
Each country was requested to give information on the
total annual number of laboratory-verified episodes of non-
typhoidal salmonellosis, S. Typhimurium, MDR S.
Typhimurium, and S. Typhimurium DT104 from 1992 to
2001. The participating countries were also asked to give
details on whether the reported number of Salmonella iso-
lates that formed the basis for further phage typing or
antimicrobial drug susceptibility testing included all nation-
al isolates or if they were a subset of isolates. If only a sub-
set of isolates were tested, the countries were asked to state
the proportion of S. Typhimurium strains tested and what
the criteria for choosing the isolates were. We also asked
participants to describe methods used for antimicrobial
drug resistance testing and the drugs included in their tests.
Multidrug-resistance was defined as isolates being
resistant or intermediately susceptible towards >4 separate
classes of drugs. This group includes isolates of R-type
ACSSuT, the so-called classical penta-resistant phenotype.
When information was available, participants were asked
to give the numbers of isolates exhibiting R-types extend-
ing the ACSSuT-complex and the number of isolates
resistant to clinically relevant antimicrobial drugs
(quinolones, trimethoprim, and cephalosporins).
In countries where only a subset of Salmonella isolates
had been submitted for phage typing, antimicrobial drug-
resistance testing, or both, the total number of DT104 or
MDR S. Typhimurium isolates was extrapolated from the
reported numbers of isolates and the proportion of tested
isolates.
Results
The questionnaire was sent to 52 countries, and a com-
pleted questionnaire was received from 29, a response rate
of 56% (Figure 1). Of the 52 invited countries, 23 were
members of or affiliated with Enter-Net; from these a pos-
itive feedback was received from 20 (87%). These coun-
tries were Australia, Austria, Belgium, Canada, Denmark,
England and Wales, Finland, Germany, Greece, Ireland,
Japan, Luxembourg, the Netherlands, New Zealand,
Norway, Scotland, South Africa, Spain, Sweden, and
Switzerland. The 8 countries and 1 regional center (31%
response rate) that participated in the survey that were not
associated with Enter-Net when data were collected were
Brazil, the Czech Republic, Hungary, Israel, Latvia, Malta,
Republic of South Korea, United States, and the Caribbean
Epidemiology Centre (CAREC), a regional center that rep-
resents 21 countries in the Caribbean (Anguilla, Antigua
and Barbuda, Aruba, Bahamas, Barbados, Belize,
Bermuda, British Virgin Islands, Cayman Islands,
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Netherlands Antilles, St. Kitts and Nevis, St. Lucia, St.
Vincent and the Grenadines, Suriname, Trinidad and
Tobago, and Turks and Caicos). For the purpose of this
study, CAREC was treated as 1 unit. The 29 participating
countries had a total population of 1.028 billion in 2001.
Surveillance
The proportion of Salmonella isolates forwarded from
local health laboratories to national or regional institutions
varied from 5% to 100%. None of the participating coun-
tries restricted the submission of isolates to strains from
selected patients, e.g., in case of septicemia or outbreak sit-
uations. All 29 participating countries performed serotyp-
ing on 85% to 100% of Salmonella isolates received at the
national reference laboratory. Table 1 shows the number of
nontyphoidal Salmonella isolates and the proportion here-
of that were S. Typhimurium in each country from 1992 to
2001 presented as 2-year intervals. The table also shows
the estimated incidence of laboratory-confirmed cases of
S. Typhimurium in 2001. Throughout the study period, the
proportion of S. Typhimurium among nontyphoidal salmo-
nellae has been relatively stable. In 1992, 16% of isolates
were  S. Typhimurium, compared to 17% in 2001.
However, large differences between countries and varia-
tions from year to year within each country made compar-
ison difficult. Nevertheless, some trends emerged when the
countries were aggregated into geographic regions. In the
Caribbean region, South America, Eastern Asia, and
Europe, a general decrease in the proportion of S.
Typhimurium was observed. In North America, on the
other hand, the situation has remained relatively stable,
whereas both Australia and New Zealand have seen an
increase in the number and proportion of S. Typhimurium
cases from 1992 to 2001.
Phage Typing
In 1992, phage typing was carried out in 6 of the partic-
ipating countries; by 2001, this number had risen to 22.
Five countries (Brazil, Japan, Norway, Switzerland, and the
United States) only performed phage typing when an MDR
strain was found or in outbreak situations. Although not all
countries performed phage typing in accordance with the
Colindale Scheme (28), the countries using different stan-
dards provided information that allowed for comparison
with results obtained using the Colindale Scheme (29–31).
The proportion of S. Typhimurium strains that were
DT104 and the proportion thereof that were found to be
MDR are shown for each country in Table 2. In general,
the incidence and proportion of DT104 increased through-
out the period. In 1992, 8.7% of S. Typhimurium isolates
were DT104, but in 2001 this proportion had increased to
33%. Again, large regional differences occurred. In the
United Kingdom, the incidence peaked in 1996 and then
decreased. In most other European countries and North
America, the relative numbers of DT104 strains had
increased throughout the period. In Australia and New
Zealand, few DT104 isolates (0.7%) were seen among S.
Typhimurium in 2001. The proportion of S. Typhimurium
strains that were DT104 is depicted in Figure 2 (the coun-
tries are aggregated into 8 regions).
Antimicrobial Drug Resistance
Antimicrobial susceptibility testing became an increas-
ingly common constituent of the surveillance during the
study period. In 1992, susceptibility testing was performed
in 14 of the 29 participating countries and in all but one in
2000. All countries routinely tested a minimum of 6
antimicrobial drugs, all belonging to different drug classes.
The majority of countries (73%) used disc diffusion testing
according to NCCLS standards. Listed by frequency, the
most common antimicrobial drug classes included in the
test panel were (fluoro)quinolones, broad-spectrum peni-
cillins, phenicols, aminoglycosides, tetracyclines,
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Figure 1. Participating countries in the survey of multidrug-resist-
ant Salmonella enterica serotype Typhimurium, 1992–2001, inter-
nationally (A) and in Europe (B).cephalosporins, sulfonamides, and trimethoprim. In 21
countries, antimicrobial susceptibility testing was per-
formed independently of phage typing results, but in 2
countries (Finland until 1999 and New Zealand), testing
was only performed on strains found to be DT104.
Table 2 shows the distribution of MDR S. Typhi-
murium presented as 2-year time-bands. Figure 3 depicts
the general trend, with countries divided into 9 different
regions. In 1992 15% of all S. Typhimurium isolates were
MDR; by 2001, this percentage had increased 3-fold to
42%. Once again, large variations occurred between coun-
tries and within countries from year to year. In most
European countries and North America, MDR S.
Typhimurium was common and, with the exception of the
United Kingdom and Ireland, multidrug resistance
increased from the mid-1990s to the end of the study peri-
od. For example, in 2001 multidrug resistance ranged
from 22% (Greece) to 72% (Ireland). Only limited data
were available from Brazil, the Caribbean region, South
Africa, and the Republic of Korea. However, in these
regions multidrug resistance was far less common, rang-
ing from zero in the Caribbean region to 19% in the
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remained low throughout the period, with 1.0% of strains
in 1997 and 3.6% in 2001.
MDR DT104 was a frequent subtype of MDR S.
Typhimurium in most of the countries. In 1992, between
11% (Germany) and 77% (Scotland) of the MDR strains
were DT104; in 2001 this ranged from 22% (Australia) to
94% (the Netherlands). Overall, the proportion of MDR
DT104 of all DT104 has remained fairly stable; 84% of
DT104 were classified as MDR in 2001, compared with
72% in 1992. Among MDR DT104, the classical penta-
resistant phenotype, R-type ACSSuT, was by far the most
common phenotype throughout the period. It was found in
99% of MDR DT104 strains in 1992 and in 94% of such
strains in 2001 (data not shown).
Finally, we looked at trends in development of addi-
tional resistance in the classical penta-resistant phenotype
(R-type ACSSuT), with focus on 3 clinically important
antimicrobial drug classes: quinolones, cephalosporins,
and trimethoprim. Both quinolone and trimethoprim resist-
ance increased in MDR DT104 throughout the study peri-
od. In 1992, nalidixic acid susceptibility testing was
International Salmonella Typhimurium DT104 Infections
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ferent countries; no resistant isolates were found. In 2001,
nalidixic acid susceptibility testing of 1,812 MDR DT104
strains in 11 countries identified 109 (6.0%) resistant
strains. Similarly, trimethoprim resistance was found in
1.2% of the 180 MDR DT104 strains tested in 1992, but in
6.6% of 1,855 MDR DT104 strains tested in 2001.
Cephalosporin-resistant MDR DT104 remained rare, with
only 0.5% resistant strains in 2001, and no clear trend
observable. Figure 4 shows the overall trend of resistance
to quinolone, trimethoprim, and cephalosporins from 1992
to 2001. The increase in quinolone resistance seen in 1996
and in 1998 was caused by a general increase in quinolone-
resistant MDR DT104 in Scotland and an outbreak of
quinolone-resistant MDR DT104 in Denmark (14), respec-
tively. The increase in trimethoprim resistance from 1995
to 1996 was also caused by a general increase in trimetho-
prim-resistant MDR DT104 in Scotland.
Discussion
The present survey was conducted to gain a better
understanding of the global impact of DT104 and MDR S.
Typhimurium, given the severity of illness than can result
from infection with S. Typhimurium and MDR strains in
particular. The survey’s primary findings are that during
the period 1992–2001, the total number of MDR S.
Typhimurium and S.Typhimurium DT104 cases increased,
while that of other types of S.Typhimurium decreased. The
total number of nontyphoidal Salmonella and  S.
Typhimurium cases also decreased. However, these gener-
al findings mask large differences in regional trends. The
collected data also may not always accurately describe the
real national incidence or be directly comparable between
countries.
The total number of isolates of nontyphoidal salmonel-
lae registered at the national level decreased from 1992 to
2001. This result may be biased because of changes in sur-
veillance practices. Since the survey indicated that surveil-
lance systems generally improved throughout the study
period, this trend is most likely correct, however.
Concurrent with this decrease, an overall decrease in the
number of S. Typhimurium isolates was observed, thus
keeping the proportion of S. Typhimurium cases among
total Salmonella cases constant. The decrease was primari-
ly seen in Europe and North America, whereas Australia
and New Zealand saw an increase in both the number of
cases of S. Typhimurium and of the total number of nonty-
phoidal Salmonella cases. In Germany the total number of
nontyphoidal Salmonella cases is available for the whole
country, but for administrative reasons data on serotypes,
antimicrobial susceptibility, and phage types are based
only on results from the new federal states of Germany
(formerly East Germany) and the city of Berlin. However,
German studies have shown that serotype distribution and
drug resistance are comparable between former West and
East Germany (32) (W. Rabsch, pers. comm.).
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Figure 2. Salmonella enterica serovar Typhimurium DT104 as per-
centage of all S. Typhimurium in 8 world regions, 1992–2001. Only
countries that had data available for 2 or more 2-year periods are
included: United Kingdom and Ireland: England and Wales,
Scotland, Ireland; Scandinavia: Denmark, Finland, Norway,
Sweden; Western Europe: Austria, Germany, and the Netherlands;
Eastern Europe: Czech Republic and Hungary; Southern Europe:
Spain and Israel; North America: Canada, United States; Eastern
Asia: the Republic of Korea; Oceania: Australia and New Zealand.
Figure 3. Multidrug-resistant Salmonella enterica serovar
Typhimurium as a percentage of all S. Typhimurium in 9 world
regions, 1992–2001. Only countries that had data available for 2
or more 2-year periods are included: United Kingdom and Ireland:
Scotland and Ireland; Scandinavia and the Baltics: Denmark,
Finland, Norway, and Latvia; Western Europe: Austria, Germany,
Luxembourg, and the Netherlands; Eastern Europe: Czech
Republic and Hungary; Southern Europe: Greece, Malta, and
Spain; North America: Canada, United States; South America:
Brazil; Eastern Asia: the Republic of Korea; Oceania: Australia.MDR S. Typhimurium has increased in the past decades
in almost all the regions covered in this study. Most of this
increase is due to the concurrent upsurge of DT104, where-
as other phage types, such as U302, DT120, DT12, and
DT193, were reported to play a smaller role in this devel-
opment. A high proportion of MDR S. Typhimurium was
primarily observed in Europe and North America. Because
of the low coverage of participating countries in Asia,
South America, and Africa, the situation in these areas was
difficult to assess. Both Australia and New Zealand, how-
ever, reported high incidence of S. Typhimurium, but MDR
strains of S. Typhimurium and DT104 were largely absent.
The isolated increase in MDR S. Typhimurium in Australia
in 2001 can be explained by a large outbreak of MDR
DT104 associated with consumption of halva (dessert
made of sesame seeds) (33). That DT104 has not spread
markedly in Australia and New Zealand may be explained
both by geography and the very strict food and livestock
import restrictions in force in these countries, which pre-
vent any large-scale introduction and spread of foreign
Salmonella types in the food animal production chain (34).
Although high and generally increasing levels of MDR
S. Typhimurium were observed in Europe, the United
Kingdom presents a special case. It and Germany had an
increase in DT104 in the beginning of the 1990s, before
most other countries (5,35). In fact, DT104 was first isolat-
ed in the United Kingdom in the early 1980s, years before
it was isolated in other countries (5). In the United
Kingdom, the incidence of DT104 peaked in 1996 and has
since declined ([5] and this study). Possible explanations
for this finding include the management of bovine spongi-
form encephalitis in the United Kingdom, associated gen-
eral improvements in farm hygiene, and an overall decline
in cattle production (36).
Although multidrug-resistance and DT104 were close-
ly linked, large country-specific differences were seen,
even between neighboring countries. Most pronounced
was the difference between Germany and the Netherlands
in 2001, where 64% and 94%, respectively, of MDR iso-
lates were DT104. Such differences probably reflect both
real differences and biases resulting from, for instance, dif-
ferent laboratory reporting practices. For example, some of
the countries in this survey (New Zealand, Norway, and
the United States) performed antimicrobial susceptibility
tests on all their DT104 isolates but only on a subset of
non-DT104 strains. 
In Australia and in Scandinavia, where the incidence of
domestically acquired salmonellosis is generally low,
many cases appeared to be imported. In a recent study of
Australian DT104 isolates, 37% were associated with trav-
el abroad, particularly to Southeast Asia (D. Lightfoot,
pers. comm.). Complete data on travel association of MDR
S. Typhimurium cases were available for Norway and
Finland and showed that most MDR S. Typhimurium
patients were infected abroad. In Sweden, where informa-
tion on DT104 but not MDR was available, most DT104
patients were infected abroad. 
A special issue concerns the possibility of acquisition,
with time, of resistance traits additional to the classical
penta-resistant pattern. Of particular concern is the addi-
tional acquisition of quinolone resistance by MDR DT104,
since fluoroquinolones are often the drugs of first choice
when treating severe salmonellosis. Our data indicate that
the prevalence of quinolone resistance has increased. As
mentioned, several studies have now shown that multidrug
resistance and quinolone resistance may be associated with
particular adverse health effects. When seen in the light of
the ability of DT104 to spread and establish itself in a large
variety of food animal lines (cattle, pigs, poultry), the
increase in the number of MDR S.Typhimurium strains that
include quinolone resistance becomes particularly prob-
lematic. Quinolone, and in particular the fluoroquinolones,
have been part of human medicine since the 1980s, result-
ing in no or very limited resistance in salmonellae. It was
not until the license of fluoroquinolones for food animal
production in the early 1990s that resistant Salmonella
strains emerged (37). The use of fluoroquinolones for food
production animals should therefore be discontinued or at
least severely restricted as quickly as possible.
This survey has several important limitations. First, it
was limited to countries with relatively sophisticated sur-
veillance systems in place, since only countries performing
phage typing or resistance testing in addition to serotyping
were eligible. This meant that Asia, Africa, and South
America were barely covered. Therefore, the survey con-
tains no representative data on the situation in these
regions. WHO Global Salm-Surv seeks to enhance the
capacity of countries to provide such data. Second, the col-
lection of isolates at the national level is likely to vary from
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Figure 4. Proportion of multidrug-resistant Salmonella enterica
serovar Typhimurium with additional resistance to quinolones,
cephalosporin, or trimethoprim, 1992–2001.country to country, depending on a number of factors such
as sampling frequency at the local level, availability of lab-
oratory reagents, and the degree to which isolates and
results are forwarded to the national level. Local practice,
the priority given to foodborne illnesses, and financial fac-
tors will influence on how often a physician will request a
fecal sample. Furthermore, many countries stated that
strains and information were not always routinely collected
centrally, while in some of the countries strains were never
forwarded from certain local laboratories. For these rea-
sons, care should be taken in the interpretation of results of
this survey; in particular when comparing incidence rates
between countries. However, these limitations are inherent
to surveillance in general and do not apply only to this sur-
vey. Cross-checking these survey data with available pub-
lished surveillance data showed them to be in line with each
other in the United States (38), the Netherlands (39), and
Denmark (40).
In summary, on a global scale, only a small number of
countries perform antimicrobial susceptibility testing or
phage typing, although the number of countries doing so
more than doubled throughout the study period. Despite its
limitations, the survey showed that the incidence of both
MDR S. Typhimurium and MDR S. Typhimurium DT104
increased markedly worldwide during the 1990s, although
the problem has primarily affected Europe and North
America. Of special concern is the increasing incidence of
quinolone-resistant S. Typhimurium. The survey implies
that MDR S. Typhimurium poses a serious and increasing
public health problem in large parts of the world.
Surveillance and control programs such as the Global
Salm-Surv international network recently launched by
WHO should therefore be reinforced.
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